Lancet

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

By Julio Rosenstock, Carol Wysham, Juan Pablo Frias, Vivian Thuyanh Thieu

Randomised trial in 478 peopleInterventions

40 weeks, double-blind, placebo-controlled, dose-response, registered NCT03954834

The paper

Julio Rosenstock, Carol Wysham, Juan Pablo Frias, Vivian Thuyanh Thieu

Dallas Diabetes Research Center; Eli Lilly (United States)

Lancet, 27 Jun 2021

doi.org/10.1016/s0140-6736(21)01324-6 PubMed 34186022

Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety